GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blum Holdings Inc (OTCPK:BLMH) » Definitions » Cash-to-Debt

Blum Holdings (Blum Holdings) Cash-to-Debt : 0.05 (As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Blum Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Blum Holdings's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.05.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Blum Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Blum Holdings's Cash-to-Debt or its related term are showing as below:

BLMH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01   Med: 0.37   Max: 6.96
Current: 0.05

During the past 13 years, Blum Holdings's highest Cash to Debt Ratio was 6.96. The lowest was 0.01. And the median was 0.37.

BLMH's Cash-to-Debt is ranked worse than
91.01% of 1046 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs BLMH: 0.05

Blum Holdings Cash-to-Debt Historical Data

The historical data trend for Blum Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Blum Holdings Cash-to-Debt Chart

Blum Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.05 1.48 0.08 0.02

Blum Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.02 0.03 0.01 0.05

Competitive Comparison of Blum Holdings's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Blum Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blum Holdings's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blum Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Blum Holdings's Cash-to-Debt falls into.



Blum Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Blum Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Blum Holdings's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Blum Holdings  (OTCPK:BLMH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Blum Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Blum Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Blum Holdings (Blum Holdings) Business Description

Traded in Other Exchanges
N/A
Address
3242 South Halladay Street, Suite 202, Santa Ana, CA, USA, 92705
Blum Holdings Inc formerly Unrivaled Brands Inc is a vertically integrated cannabis multi-state operator having a cannabis brand spanning consumer products, cultivation, distribution, and retail. Its brands include Korova, Sticks, and Cabana, among others. It operates leading dispensaries throughout the state as well as several leading company-owned brands including Korova, known for its high potency products across multiple product categories.
Executives
Patty Chan officer: CHIEF FINANCIAL OFFICER 11516 DOWNEY AVE, DOWNEY CA 90241
Oren Schauble officer: President 3242 S HALLADAY ST., SUITE 202, SANTA ANA CA 92705
Dallas Imbimbo director 1800 NEWPORT CIRCLE, SANTA ANA CA 92705
Eric Baum director 866 BERKSHIRE DRIVE, WESTBURY NY 11590
Tiffany N. Davis director 11852 MANHATTAN CT., RANCHO CUCAMONGA CA 91730
Michael Nahass director 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Derek Peterson director, officer: President and CEO 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Alan David Gladstone other: Former Director of Issuer P.O BOX 9699, NEWPORT BEACH CA 92658
Uri Kenig officer: Chief Operating Officer 2040 MAIN ST., SUITE 225, IRVINE CA 92614
Ira E. Ritter director C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
Nicholas Kovacevich director 2618 SAN MIGUEL DRIVE, #480, NEWPORT BEACH CA 92660
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Jeffrey Robert Batliner officer: Chief Financial Officer 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Megan Jimenez officer: Chief Financial Officer 2040 MAIN ST., SUITE 225, IRVINE CA 92614
Matthew Morgan director, officer: Chief Executive Officer 2040 MAIN STREET, SUITE 225, IRVINE CA 92614